Talquetamab (tal) plus daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.

被引：0

作者：

Dholaria, Bhagirathbhai R.

Weisel, Katja

Mateos, Maria-Victoria

Goldschmidt, Hartmut

Martin, Thomas G.

Morillo, Daniel

Reece, Donna Ellen

Rodriguez-Otero, Paula

Bhutani, Manisha

D'Souza, Anita

Oriol, Albert

Rosinol, Laura

Bahlis, Nizar J.

Bakshi, Kalpana

Kang, Lijuan

Vandenberk, Lien

Smit, Marie-Anne Damiette

Wasch, Ralph

van de Donk, Niels W. C. J.

Chari, Ajai

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[3] Univ Hosp Salamanca, Salamanca, Spain

[4] Univ Klinikum Heidelberg, Med Klin 5, Heidelberg, Germany

[5] Natl Ctr Tumorerkrankungen, Heidelberg, Germany

[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco Med Ctr, San Francisco, CA USA

[7] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

[8] Princess Margaret Canc Ctr, Toronto, ON, Canada

[9] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[10] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[11] Med Coll Wisconsin, Milwaukee, WI USA

[12] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

[13] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain

[14] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[15] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[16] Janssen Res & Dev, Spring House, PA USA

[17] Janssen Res & Dev, Antwerp, Belgium

[18] Janssen Biol Europe, Leiden, Netherlands

[19] Freiburg Univ, Med Ctr, Freiburg, Germany

[20] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands

[21] Mt Sinai Sch Med, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8003

引用

页数：1

共 50 条

[31] Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)
Yimer, Habte
Melear, Jason
Faber, Edward
Bensinger, William
Burke, John M.
Narang, Mohit
Stevens, Don
Gunawardena, Sriya W.
Lutska, Yana
Qi, Keqin
Ukropec, Jon
Qi, Ming
Lin, Thomas
Rifkin, Robert M.
BLOOD, 2018, 132
[32] Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
Schinke, Carolina D.
Touzeau, Cyrille
Minnema, Monique C.
van de Donk, Niels W. C. J.
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Rasche, Leo
Ye, Jing Christine
Vishwamitra, Deeksha
Ma, Xuewen
Qin, Xiang
Campagna, Michela
Masterson, Tara J.
Hilder, Brandi
Tolbert, Jaszianne A.
Renaud, Thomas
Goldberg, Jenna
Heuck, Christoph
Chari, Ajai
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[33] Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)
Yimer, Habte
Melear, Jason
Faber, Edward
Bensinger, William I.
Burke, John M.
Gunawardena, Sriya
Sean, Murphy
Parros, Hollee
Lutska, Yana
Darif, Mohamed
Londhe, Anil
Qi, Ming
Ukropec, Jon
Lin, Thomas
Rifkin, Robert M.
BLOOD, 2017, 130
[34] Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001
Facon, Thierry
Lonial, Sagar
Weiss, Brendan M.
Suvannasankha, Attaya
Fay, Joseph
Arnulf, Bertrand
Ifthikharuddin, Jainulabdeen J.
de Boer, Carla
Wang, Jianping
Wu, Kaida
Chari, Ajai
Lentzsch, Suzanne
Schecter, Jordan
Krishnan, Amrita
BLOOD, 2017, 130
[35] Healthcare Resource Use and Costs Among Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Romanus, Dorothy
Seal, Brian
Jhaveri, Mehul
Labotka, Richard
Henk, Henry
BLOOD, 2015, 126 (23)
[36] Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
Hungria, Vania T. M.
Weisel, Katja
Radinoff, Atanas
Delimpasi, Sosana
Mikala, Gabor
Masszi, Tamas
Li, Jian
Capra, Marcelo
Maiolino, Angelo
Pappa, Vasiliki
Chraniuk, Dominik
Osipov, Iurii
Leleu, Xavier
Low, Michael
Kouri, Fotini
Liboon, John
Brawley, Chris
Lewis, Eric
Tubel, Gabriela
Li, Mary
McKeown, Astrid
Roy-Ghanta, Sumita
Opalinska, Joanna
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S261 - S262
[37] Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1.
Ma, Xuewen
Gong, Jue
Zhou, Jie
Yuan, Dongfen
Vishwamitra, Deeksha
Hilder, Brandi
Masterson, Tara J.
Tolbert, Jaszianne A.
Renaud, Thomas
Heuck, Christoph
Kane, Colleen
Samtani, Mahesh N.
Girgis, Suzette
Berdeja, Jesus G.
Krishnan, Amrita Y.
Ouellet, Daniele
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[38] ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM)-Optimal dose, updated efficacy and safety results.
Hajek, Roman
Pour, Ludek
Granell, Miquel
Maisnar, Vladimir
Richardson, Paul G.
Norin, Stefan
Sydvander, Malin
Obermueller, Jakob
Ocio, Enrique M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).
Lokhorst, Henk M.
Laubach, Jacob
Nahi, Hareth
Plesner, Torben
Gimsing, Peter
Hansson, Markus
Minnema, Monique
Lassen, Ulrik Niels
Krejcik, Jakub
Ahmadi, Tahamtan
Lisby, Steen
Basse, Linda
Brun, Nikolai C.
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[40] Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.
Nahi, Hareth
Usmani, Saad Zafar
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Yang, Shiyi
Hellemans, Peter
Tromp, Brenda J.
Luo, Man
Zemlickis, Donna
Farnsworth, Andrew
Chari, Ajai
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →